Dr. Phil Belgrader is a Sr. Director at Muse Bio, a next generation genome editing company. He is a serial entrepreneur and inventor with a broad background in developing new bioinstrumentation, assays, and front-end sample preparation for Life Sciences, Diagnostics, Forensics, and Biodefense. He received his Ph.D. in Cell and Molecular Biology from the University at Buffalo and was a Neuromuscular Disease Research Fellow at Roswell Park Cancer Institute. Dr. Belgrader served as a USAF officer and Chief of the Advanced Technologies Development Branch of the Armed Forces DNA Identification Laboratory. Dr. Belgrader has held key roles in early stage R&D leading to products that include the 10X Genomics Chromium platform, Bio-Rad droplet digital PCR system, Cepheid GeneXpert, Northrop Grumman Biohazard Detection System, Applied Biosystems SNPlex, Smiths Bio-Seeq, and Akonni TruTip and TruArray products.
Dr. Gail H. Cassell is Senior Lecturer in the Department of Global Health and Social Medicine, Harvard Medical School, Senior Scientist, Division Global Health Equity, Brigham and Women’s Hospital Boston, and Vice President of TB Drug Development of the not-for- profit Infectious Disease Research Institute (IDRI) in Seattle. Dr. Cassell served as Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases at Eli Lilly and Company in Indianapolis where she was responsible for launching the Lilly MDR-TB philanthropic effort and establishing and leading the Lilly TB Drug Discovery Initiative, a nonprofit launched in 2007. Formerly she was Vice President of Infectious Diseases Drug Discovery and Clinical Development at Lilly, where she led a hepatitis C protease inhibitor program from the discovery phase to clinical candidate, and the development of a new antibiotic from clinical development to product decision. Prior to Lilly, Gail served as the Charles H. McCauley Professor and Chairman of the Department of Microbiology at the University of Alabama Schools of Medicine and Dentistry at Birmingham. Dr. Cassell has served on many boards and committees including past President of the American Society for Microbiology, the Board of Scientific Councilors of the CDC, Secretary of Health and Human Services Advisory Council of Public Health Preparedness, the FDA’s Science Board, and is currently a member of the NIH Science Management Board, the newly appointed NIH Board of Trustees, and the Advisory Council of the Fogarty International Center of NIH. A member of the Institute of Medicine of the National Academy of Sciences, Gail has been widely recognized for her research accomplishments including two honorary degrees.
Dr. Davis is currently the Senior Medical Adviser, Division of Clinical Studies, at DHHS/ASPR/BARDA. In this role, Dr. Davis reviews all BARDA programs that involve clinical activities and represents the Division of Clinical Studies to ensure all clinical trials meet the requirements for reliably demonstrating safety and efficacy in compliance with good clinical practice, as well as reviewing and analyzing safety data relevant to BARDA contracts. He is involved in clinical trial protocol design discussions, implementation, analysis, oversight and discussion of cohort populations, clinical endpoints, clinical assays, and adverse events within clinical development programs; he serves as liaison on clinical studies with contractors and other HHS agencies (especially FDA, CDC and NIH). Dr. Davis is a senior business executive & physician-scientist with successful leadership roles in the fields of therapeutics, diagnostics, detection and medical devices, with expertise in infectious diseases, emergency preparedness & consequence management. Dr. Davis created, led and managed a medical biotechnology business focused on developing an entirely new generation of anti-viral drugs where he spearheaded DoD/DTRA contract wins & Congressional support of $20M, with follow-on of $36M. Dr. Davis managed a uniquely successful NATO multi-national drug development program and was awarded the Royal Navy’s Erroll-Eldridge Prize for his accomplishments. Dr. Davis is a co-discoverer of the mechanism of action of the novel cancer therapy anti-emetic (Kytril/Zofran), now in world-wide use and was awarded the Gilbert-Blane Gold Medal of Royal Colleges of Physicians & Surgeons in recognition. Dr. Davis was the co-debriefer of the first-ever defector from the Soviet BW Program, he organized and led the technical intelligence element of the first-ever US-UK diplomatic initiative to bring FSU/Russia into compliance with the Biological & Toxin Weapons Convention and was ultimately recognized for this major accomplishment with the award of the Order of The British Empire (OBE) by Her Majesty Queen Elizabeth II.
Dr. Korth is currently Professor at the University of Düsseldorf Medical School, Germany, where he leads a laboratory doing fundamental research in protein pathology and molecular psychiatry. He received an M. D. from the LMU Munich, Germany in 1995 and a Ph.D. from the VU Amsterdam, Netherlands in 2006. He received clinical training as resident for psychiatry at the Max Planck Institute for Psychiatry, Munich, Germany and in biochemistry and molecular biology at the University of Zurich, Switzerland, and University of California San Francisco in the lab of Nobel Laureate Stanley Prusiner. Dr. Korth is a board certified psychiatrist and co-founder the company Prionics, Switzerland, who was the first to develop prion testing for bovine spongiform encephalopathy. His current reserarch focus is on biological diagnostics of mental illesses, as well as the development of novel therapies for these diseases targeting their protein pathology.
Dr. Lingappa is currently Chief Technology Officer and Co‐CEO of Prosetta Biosciences, Inc. In these roles he is responsible for the advancement of all of Prosetta’s drug discovery and development programs. He received a B.A. degree with High Honors from Swarthmore College in 1975, a Ph.D. degree from The Rockefeller University in 1979 under the mentorship of Guenter Blobel (Nobel Laureate, 1999), and a M.D. degree from Cornell University Medical College in 1980. He completed residency training in Internal Medicine in 1982, then joined the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF), where he ran an NIH-funded basic research laboratory for over 20 years. Dr. Lingappa practiced internal medicine at San Francisco General Hospital for over 26 years. He is recipient of a Kaiser Award for excellence in teaching (1990), is a Fellow of the American Association for the Advancement of Science (2004), and is Emeritus Professor of Physiology at UCSF.
Ronald J. Pion, MD served as Akonni’s Chairman of the Board for 5 years. Dr. Pion currently offers strategic assistance to companies involved in the virtual practice of medicine. He serves as an advisor to several healthcare investment capital firms. Ron has been involved in the development and production of television/radio and other interactive electronic programming for health care professionals and patients for more than 40 years. As a gifted teacher, he’s been dedicated to facilitating learning on the part of patients and their families, assisting in disease prevention, health promotion and wellness enhancement. Following a successful career in academic medicine, serving on the faculties of the University of Washington and the University of Hawaii, Dr. Pion returned to Los Angeles in 1979 to pursue healthcare telecommunications on a full-time basis. He served as medical correspondent for KNBC’s Alive and Well, was the founder of Hospital Satellite Network, and co-developed and hosted a nationally syndicated, daily television series, Group One Medical. He is a clinical professor at the UCLA School of Medicine, and a Fellow of the American College of Obstetricians and Gynecologists.
TruDiagnosis Systems, TruDx Readers, TruArray Tests, TruTip Kits, Primers, Lysis and Binding Buffers, Wash Buffers and Elution Buffers: For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.